PMS2 and ovarian cancer: Data from the Prospective Lynch Syndrome Database indicate that individuals carrying heterozygous pathogenic PMS2 variants do not exhibit an elevated risk of developing colorectal, endometrial, or ovarian cancer prior to the age of 50.